Dimethyl Sulfoxide: An Effective Penetration Enhancer for Topical Administration of NSAIDs

References

• . Fischer JM. DMSO: a review. US Pharmacist. 1981;25–32
   Google Scholar
• . Davis PW. An incipient “wonder drug” movement: DMSO and the Food and Drug Administration. Soc Problems. 1984;32(2):197–212
   Google Scholar
• . Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol. 2003;65(7):1035–1041
   PubMed Web of Science ®Google Scholar
• . Rosenstein ED. Topical agents in the treatment of rheumatic disorders. Rheum Dis Clin North Am. 1999;25(4):899–918, viii
   PubMedGoogle Scholar
• . Ikeda Y, Long DM. Comparative effects of direct and indirect hydroxyl radical scavengers on traumatic brain oedema. Acta Neurochir Suppl (Wien). 1990;51:74–76
   PubMedGoogle Scholar
• . Shirley SW, Stewart BH, Mirelman S. Dimethyl sulfoxide in treatment of inflammatory genitourinary disorders. Urology. 1978;11(3):215–220
   PubMedGoogle Scholar
• . Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1997;73(2):123–139
   PubMed Web of Science ®Google Scholar
• . McKim AS, Strub R. Dimethyl sulfoxide USP, PhEur in approved pharmaceutical products and medical devices. Pharm Tech. 2008;1–8
   Google Scholar
• . Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603–618
   PubMed Web of Science ®Google Scholar
• . Wiechers JW. The barrier function of the skin in relation to percutaneous absorption of drugs. Pharm Weekbl Sci. 1989;11(6):185–198
   PubMedGoogle Scholar
• . Pathan IB, Setty CM. Chemical penetration enhancers for transdermal delivery systems. Trop J Pharm Res. 2009;8:173–179
   Web of Science ®Google Scholar
• . Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002–2012
   PubMed Web of Science ®Google Scholar
• . Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238–245
   PubMed Web of Science ®Google Scholar
• . Notman R, den Otter WK, Noro MG, Briels WJ, Anwar J. The permeability enhancing mechanism of DMSO in ceramide bilayers simulated by molecular dynamics. Biophys J. 2007;93(6):2056–2068
   PubMed Web of Science ®Google Scholar
• . Kaushik D, Batheja P, Kilfoyle B, Rai V, Michniak-Kohn B. Percutaneous permeation modifiers: enhancement versus retardation. Expert Opin Drug Deliv. 2008;5(5):517–529
   PubMed Web of Science ®Google Scholar
• . Asbill CS, Michniak BB. Percutaneous penetration enhancers: local versus transdermal activity. Pharm Sci Technol Today. 2000;3(1):36–41
   PubMedGoogle Scholar
• . Gurtovenko AA, Anwar J. Modulating the structure and properties of cell membranes: the molecular mechanism of action of dimethyl sulfoxide. J Phys Chem B. 2007;111(35):10453–10460
   PubMed Web of Science ®Google Scholar
• . Gurtovenko AA, Anwar J, Vattulainen I. Defect-mediated trafficking across cell membranes: insights from in silico modeling. Chem Rev. 2010;110(10):6077–6103
   PubMedGoogle Scholar
• . Hucker HB, Miller JK, Hochberg A, Brobyn RD, Riordan FH, Calesnick B. Studies on the absorption, excretion and metabolism of dimethylsulfoxide (DMSO) in man. J Pharmacol Exp Ther. 1967;155(2):309–317
   PubMedGoogle Scholar
• . Ursin C, Hansen CM, Van Dyk JW, Jensen PO, Christensen IJ, Ebbehoej J. Permeability of commercial solvents through living human skin. Am Ind Hyg Assoc J. 1995;56(7):651–660
   PubMed Web of Science ®Google Scholar
• . Anchordoguy TJ, Carpenter JF, Crowe JH, Crowe LM. Temperature-dependent perturbation of phospholipid bilayers by dimethylsulfoxide. Biochim Biophys Acta. 1992;1104(1):117–122
   PubMedGoogle Scholar
• . Yu ZW, Quinn PJ. Solvation effects of dimethyl sulphoxide on the structure of phospholipid bilayers. Biophys Chem. 1998;70(1):35–39
   PubMed Web of Science ®Google Scholar
• . Gordeliy VI, Kiselev MA, Lesieur P, Pole AV, Teixeira J. Lipid membrane structure and interactions in dimethyl sulfoxide/water mixtures. Biophys J. 1998;75(5):2343–2351
   PubMedGoogle Scholar
• . Sum AK, de Pablo JJ. Molecular simulation study on the influence of dimethylsulfoxide on the structure of phospholipid bilayers. Biophys J. 2003;85(6):3636–3645
   PubMedGoogle Scholar
• . Notman R, Noro M, O'Malley B, Anwar J. Molecular basis for dimethylsulfoxide (DMSO) action on lipid membranes. J Am Chem Soc. 2006;128(43):13982–13983
   PubMed Web of Science ®Google Scholar
• . Hewitt PG, Poblete N, Wester RC, Maibach HI, Shainhouse JZ. In vitro cutaneous disposition of a topical diclofenac lotion in human skin: effect of a multi-dose regimen. Pharm Res. 1998;15(7):988–992
   PubMedGoogle Scholar
• . Hui X, Hewitt PG, Poblete N, Maibach HI, Shainhouse JZ, Wester RC. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res. 1998;15(10):1589–1595
   PubMedGoogle Scholar
• . Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. 2004;171(4):333–338
   PubMed Web of Science ®Google Scholar
• . Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord. 2005;6:44
   PubMed Web of Science ®Google Scholar
• . Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164(18):2017–2023
   PubMedGoogle Scholar
• . Rubin LF. Toxicologic update of dimethyl sulfoxide. Ann N Y Acad Sci. 1983;411:6–10
   PubMed Web of Science ®Google Scholar
• . US Environmental Protection Agency. Robust summaries and test plans: dimethyl sulfoxide. September 2003. http://www.epa.gov/chemrtk/pubs/summaries/dimthslf/c14721tc.htm. Accessed May 25, 2011
   Google Scholar
• . Gaylord Chemical Company LLC. DMSO: dimethyl sulfoxide health and safety information bulletin 106B. October 2007. http://www.gaylordchemical.com/bulletins/Bulletin106B/index.php. Accessed May 25, 2011
   Google Scholar
• . Smith ER, Hadidian Z, Mason MM. The single—and repeated—dose toxicity of dimethyl sulfoxide. Ann N Y Acad Sci. 1967;141(1):96–109
   PubMedGoogle Scholar
• . Pennsaid [package insert]. Hazelwood, MO: Mallinckrodt Inc.; 2010
   Google Scholar
• . Brayton CF. Dimethyl sulfoxide (DMSO): a review. Cornell Vet. 1986;76(1):61–90
   PubMedGoogle Scholar
• . Kligman AM. Topical pharmacology and toxicology of dimethyl sulfoxide. 1. JAMA. 1965;193:796–804
   PubMed Web of Science ®Google Scholar
• . Bertelli G, Gozza A, Forno GB, . Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol. 1995;13(11):2851–2855
   PubMedGoogle Scholar
• . Jacob SW, Herschler R. Dimethyl sulfoxide after twenty years. Ann N Y Acad Sci. 1983;411:xiii–xvii
   PubMedGoogle Scholar
• . Vogin EE, Carson S, Cannon G, Linegar CR, Rubin LF. Chronic toxicity of DMSO in primates. Toxicol Appl Pharmacol. 1970;16(3):606–612
   PubMed Web of Science ®Google Scholar
• . Brobyn RD. The human toxicology of dimethyl sulfoxide. Ann N Y Acad Sci. 1975;243:497–506
   PubMedGoogle Scholar
• . Garcia CA. Ocular toxicology of dimethyl sulfoxide and effects on retinitis pigmentosa. Ann N Y Acad Sci. 1983;411:48–51
   PubMedGoogle Scholar
• . Shirley HH, Lundergan MK, Williams HJ, Spruance SL. Lack of ocular changes with dimethyl sulfoxide therapy of scleroderma. Pharmacotherapy. 1989;9(3):165–168
   PubMedGoogle Scholar